Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 For Receipt Of BSE IP Approval
Filed with BSE · · 3 pages · English
Summary by 6ix AI
Chandra Bhagat Pharma Ltd. has announced the receipt of in-principle approval from BSE for a preferential issue of convertible warrants. The approval allows the company to issue a specified number of warrants convertible into equity shares at a set price to both promoters and non-promoters.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chandra Bhagat Pharma Ltd. on 6ix
Earlier from Chandra Bhagat Pharma
- Closure of Trading Window
- Chandra Bhagat Pharma Ltd. Press Release Oct 01 2026
- Chandra Bhagat Pharma Ltd. Press Release Sep 01 2026
- Chandra Bhagat Pharma Ltd. Press Release Aug 06 2026
- Chandra Bhagat Pharma Ltd. Press Release Aug 05 2026
Later from Chandra Bhagat Pharma
- Certificate For Non-Applicability Of Corporate Governance For The Quarter Ended 30Th September, 2026.
- Announcement under Regulation 30 (LODR)-Allotment
Follow Chandra Bhagat Pharma into a list and get an email when it puts out news.
Follow Chandra Bhagat Pharma